Currently, there are tyrosine kinase inhibitors that act on MET, for example, capmatinib, as shown by the GEOMETRY mono-1 clinical trial, with response rates of 68% in targeted therapy-naive patients and a median progression-free survival of 12.4 months after first-line treatment for NSCLC with MET mutation [91]. This evidence concerns the gene MET and non-small cell lung carcinoma.